Lisata Therapeutics
LSTA
47 hedge funds and large institutions have $6.13M invested in Lisata Therapeutics in 2015 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 9 reducing their positions, and 3 closing their positions.
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
9% more funds holding
Funds holding: 43 → 47 (+4)
30% less capital invested
Capital invested by funds: $8.76M → $6.13M (-$2.63M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $52K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
+$101K |
| 2 |
Millennium Management
New York
|
+$98.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$56.7K |
| 4 |
Nomura Holdings
Tokyo,
Japan
|
+$45.9K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$44.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$544K |
| 2 |
PRCM
Pine River Capital Management
Minnetonka,
Minnesota
|
-$184K |
| 3 |
VKH
Virtu KCG Holdings
New York
|
-$44.4K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$41.1K |
| 5 |
TSS
Two Sigma Securities
New York
|
-$26K |
LSTA Hedge Fund Activity: Q4 2015 in Review
47 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Lisata Therapeutics (LSTA) for Q4 2015, worth a combined $6.13M — down 30% from $8.76M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new LSTA positions and 3 closed out — a net gain of 4 holders — while 12 added to existing stakes and 9 trimmed.
The largest buyer was D.E. Shaw & Co, adding an estimated $101K. The largest seller was Knoll Capital Management, cutting an estimated $544K.
- 47 institutional investors held Lisata Therapeutics (LSTA) as of Q4 2015, up from 43 in Q3 2015.
- Funds reported $6.13M of Lisata Therapeutics stock for Q4 2015, down 30% quarter-over-quarter.
- 7 funds opened new Lisata Therapeutics positions in Q4 2015 and 3 closed out, a net change of +4 holders.
- The largest Lisata Therapeutics buyer in Q4 2015 was D.E. Shaw & Co, an estimated $101K added.
- The largest Lisata Therapeutics seller in Q4 2015 was Knoll Capital Management, an estimated $544K sold.
Based on aggregated 13F filings for Q4 2015.